Friday, July 10, 2026
🇺🇸 FDA

pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis

PARItec

Pari Pharma GmbH

PARItec clinical programs — 248 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
Status
Public
HQ
Starnberg, DE
Employees
28
Programs
248
Drugs
362
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

PARItec projects

248 ClinicalTrials.gov programs sponsored by PARItec.

PARItec has 248 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

248 programs

Clinical programs

Page 5 of 6

  1. DIMETHYL FUMARATE, DIMETHYL FUMARATE

    Pari Pharma GmbH

    Macular degeneration

    phase 2 small molecule active

    1 trial

  2. Dream01, IMATINIB

    Pari Pharma GmbH

    SCD severe patients

    phase 2 small molecule active

    1 trial

  3. EXAFIP2

    Pari Pharma GmbH

    IDIOPATHIC PULMONARY FIBROSIS

    phase 2 small molecule active

    1 trial

  4. Enema transplant of fecal microbiota 25g/100mL

    Pari Pharma GmbH

    Austistic spectrum disorder

    phase 2 small molecule active

    1 trial

  5. Epidyolex 100 mg/ml oral solution

    Pari Pharma GmbH

    Children and adolescents with severe neurodevelopmental disorders

    phase 2 small molecule active

    1 trial

  6. FEBUXOSTAT, ALLOPURINOL

    Pari Pharma GmbH

    Gout adult patients

    phase 2 small molecule active

    1 trial

  7. GADOTERIC ACID, [18F]fludarabine

    Pari Pharma GmbH

    Patients with newly diagnosed primary central nervous system lymphoma naïve to surgery, radiotherapy or chemotherapy

    phase 2 small molecule active

    1 trial

  8. GRAALL2014

    Pari Pharma GmbH

    Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)

    phase 2 other active

    1 trial

  9. ILT-101 liquide, Placebo of ILT-101

    Pari Pharma GmbH

    Autism Spectrum disorder ASD

    phase 2 small molecule active

    1 trial

  10. ISATUXIMAB

    Pari Pharma GmbH

    Isatuximab in type I cryoglobulinaemia: A prospective pilot study

    phase 2 small molecule active

    1 trial

  11. Itacitinib

    Pari Pharma GmbH

    Adults patients having non severe HLH

    phase 2 small molecule active

    1 trial

  12. Itacitinib, placebo of itacitinib 100mg

    Pari Pharma GmbH

    Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screening

    phase 2 small molecule active

    1 trial

  13. Jakavi 15 mg tablets, Placebo of Jakavi 15mg

    Pari Pharma GmbH

    Inclusion body Myositis

    phase 2 small molecule active

    1 trial

  14. Jakavi tablets for haemophagocytic lymphohistiocytosis (HLH) in children

    Pari Pharma GmbH

    haemophagocytic lymphohistiocytosis (HLH) in children

    phase 2 small molecule active

    1 trial

  15. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eligible for PA and comprising at least one of the following criteria: - Single tumour>3 cm≤ 5cm or - multiple tumours (max 3 lesions ≤ 3cm) or - Single tumour between 2 and 3 cm with at least one of the following characteristic: • Serum AFP>100 ng/mL • Infiltrative form • Macro-trabecular subtype (if applicable)

    phase 2 small molecule active

    1 trial

  16. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Non-resectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  17. METFORMIN , Placebo 515

    Pari Pharma GmbH

    Portal hypertension (PHT) and consequences in complications of cirrhosis

    phase 2 small molecule active

    1 trial

  18. Oxbryta 500 mg film-coated tablets

    Pari Pharma GmbH

    sickle cell disease

    phase 2 small molecule active

    1 trial

  19. P120142

    Pari Pharma GmbH

    Patient with newly diagnosed (≤ 3 months) type 1 diabetes stage 3

    phase 2 small molecule active

    1 trial

  20. P150941J

    Pari Pharma GmbH

    Adults diagnosed with SJS-TEN with at least 10% of body surface area involved

    phase 2 small molecule active

    1 trial

  21. P160906J

    Pari Pharma GmbH

    Patients displaying a non-classified, severe and resistant inflammatory disease

    phase 2 small molecule active

    1 trial

  22. P160909

    Pari Pharma GmbH

    Takayasu arteritis

    phase 2 small molecule active

    1 trial

  23. P160954J

    Pari Pharma GmbH

    Adults with non-contrast-enhancing diffuse brainstem gliomas with non-threatening infiltrative clinical and/or radiological progression, Adult brain stem gliomas

    phase 2 other active

    1 trial

  24. P170922J

    Pari Pharma GmbH

    Minimal Change Nephrotic Syndrom

    phase 2 small molecule active

    1 trial

  25. PEMBROLIZUMAB

    Pari Pharma GmbH

    Kaposi's sarcoma

    phase 2 small molecule active

    1 trial

  26. Placebo de macitentan 10 mg, MACITENTAN

    Pari Pharma GmbH

    Inoperable Chronic thromboembolic pulmonary hyperTension, Pneumology

    phase 2 small molecule active

    1 trial

  27. RAVICTI 1.1 g/ml oral liquid

    Pari Pharma GmbH

    Pyruvate dehydrogenase deficiency

    phase 2 small molecule active

    1 trial

  28. RUBIDIUM CHLORIDE

    Pari Pharma GmbH

    Kidney carcinoma

    phase 2 small molecule active

    1 trial

  29. SARCLISA 20mg/mL concentrate for solution for infusion.

    Pari Pharma GmbH

    Pure cell red aplasia by major ABO mismatch after allogeneic hematopoietic stem cell transplantation

    phase 2 small molecule active

    1 trial

  30. SIROLIMUS

    Pari Pharma GmbH

    Adult patients (men and women) (≥ 18 years of age) with cutaneous sarcoidosis involving the face

    phase 2 small molecule active

    1 trial

  31. volrustomig, Monalizumab

    Pari Pharma GmbH

    cancerology

    phase 2 small molecule active

    1 trial

  32. APHP 211033

    Pari Pharma GmbH

    Cardiology and vascular disease

    phase 1 other active

    1 trial

  33. APHP191116

    Pari Pharma GmbH

    hematologic malignancies ; acute myeloid leukemias

    phase 1 other active

    1 trial

  34. APHP200034

    Pari Pharma GmbH

    Non-ischemic Dilated Cardiomyopathies

    phase 1 other active

    1 trial

  35. CITY

    Pari Pharma GmbH

    Cutaneous T-cell lymphomas (CTCL)

    phase 1 other active

    1 trial

  36. Dose dense re-challenge of high dose methotre...

    Pari Pharma GmbH

    Oncology: RELAPSED PRIMARY CNS LYMPHOMA

    phase 1 other active

    1 trial

  37. MEDITOP/2025/01

    Pari Pharma GmbH

    Comparative bioequivalence study in healthy volunteers under fasting conditions.

    phase 1 other active

    1 trial

  38. MUNC13.4-CD34 suspension, MUNC13.4-T3 suspension

    Pari Pharma GmbH

    Familial Hemophagocytic Lymphohistiocytosis (FHL)

    phase 1 small molecule active

    1 trial

  39. SPVN20-CLIN-01

    Pari Pharma GmbH

    End-stage rod-cone dystrophy

    phase 1 other active

    1 trial

  40. AMOXICILLIN

    Pari Pharma GmbH

    Adults diagnosed with lower limbs erysipelas

    approved small molecule active

    1 trial

  41. APHP 190183

    Pari Pharma GmbH

    Crohn’s disease

    approved small molecule active

    1 trial

  42. APHP180618

    Pari Pharma GmbH

    Asymptomatic Patients with frequent PVCs and normal LVEF

    approved small molecule active

    1 trial

  43. APHP200002

    Pari Pharma GmbH

    Patients with excessive supraventricular ectopies or short atrial runs (ESVEA) defined as ≥ 1% premature atrial contractions (PAC) /24 hours or any atrial runs ≥ 20 PACs (but shorter than 30 seconds) on a 24-hour Holter ECG monitoring and CHA2DS2VASC score ≥ 3. Patients with any atrial runs ≥ 20 PACs but shorter than 30 seconds on a 15-21 days Holter ECG monitoring and CHA2DS2VASC score ≥ 3 may also be included in the Short-Run trial.

    approved small molecule active

    1 trial

  44. APHP200020

    Pari Pharma GmbH

    Pyelonephritis, Kidney Transplant recipients

    approved small molecule active

    1 trial

  45. APHP210085

    Pari Pharma GmbH

    EA-COPD (with mechanical ventilation, invasive or non-invasive, or high-flow nasal oxygen therapy).

    approved small molecule active

    1 trial

  46. APHP220806

    Pari Pharma GmbH

    Women who delivered by caesarean and have a moderate postpartum iron deficiency anaemia defined by 8.0 g/dL ≤ postoperative Hb level ≤ 10.0 g/dL within 72h after delivery and a ferritinemia ≤ 100 ng/mL OR transferrin saturation ≤ 20% (Measured after postoperative Hb level measurement)

    approved small molecule active

    1 trial

  47. BILINDA GYNIAL 0 for Hormonal contraception

    Pari Pharma GmbH

    Hormonal contraception

    approved small molecule active

    1 trial

  48. CEFAZOLIN

    Pari Pharma GmbH

    Infection prophylaxis

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does PARItec have?

248 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.